PPI-clarithromycin-amoxicillin triple therapy — 14 days

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OMEPRAZOLE` `DRUG-CLARITHROMYCIN` `DRUG-AMOXICILLIN`

ID	`REG-HP-PPI-CLAR-AMOX`
Type	Regimen
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-AGA-H-PYLORI-2024` `SRC-MAASTRICHT-VI-FLORENCE-2022` `SRC-NCCN-BCELL-2025`

Notes

Standard PPI-clarithromycin-amoxicillin triple therapy for H. pylori eradication. Preferred only in regions with clarithromycin resistance ≤15%. In Ukraine and most of Eastern Europe, clarithromycin resistance is >15% — Maastricht VI/Florence Consensus 2022 recommends PBMT (REG-HP-BISMUTH-QUADRUPLE) as first-line instead.

Used By

Access Pathways

AP-HP-ERADICATION-PHARMACY-OOP - H. pylori eradication (PPI + amox/clarithromycin / bismuth quadruple) — pharmacy out-of-p...

Indication

IND-H-PYLORI-PREVENTION-ERADICATION - IND-H-PYLORI-PREVENTION-ERADICATION